<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03235258</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS CO10 EPF</org_study_id>
    <nct_id>NCT03235258</nct_id>
  </id_info>
  <brief_title>Cohort of HIV-infected Children</brief_title>
  <acronym>EPF</acronym>
  <official_title>ANRS CO10 EPF - Cohort of HIV-infected Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the conditions of access to early treatment of
      children infected with HIV, their management on the long-term, and impact on growth, clinical
      and immunovirological prognosis, adherence to treatment, living conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CO10 EPF paediatric cohort includes therapeutic, clinical and biological detailed
      questionnaires. The data are collected by the doctors every three months to 2 years and then
      every 6 months until to 18 years or every year by a simplified questionnaire if medical
      follow up continues outside of a participating site.

      After 18 years of age, the patients are eligibile for the ANRS CO19-Coverte cohort.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Conditions of access to early treatment</measure>
    <time_frame>At inclusion and every six months up to 18 years</time_frame>
    <description>social factors (Geographical origin, living conditions, school level, age) and infection stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Puberty stage</measure>
    <time_frame>At 8 years and every six months up to 18 years</time_frame>
    <description>Tanner classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical prognosis</measure>
    <time_frame>At inclusion and every six months up to 18 years</time_frame>
    <description>Health status (lipodystrophy, metabolic abnormalities, cardiovascular diseases, encephalopathy, Developmental delay, CDC stage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immuno virological prognosis</measure>
    <time_frame>At inclusion and every six months up to 18 years</time_frame>
    <description>HIV RNA&lt;50c/mL, CD4 cells count &gt; 500 cells/mL, Genotypic resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis of patient coinfected by CMV or VHC</measure>
    <time_frame>At inclusion and every six months up to 18 years</time_frame>
    <description>Adverse events of treatments (complications)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexuality</measure>
    <time_frame>At 15 years and every six months up to 18 years</time_frame>
    <description>sexual risk behaviour (age at first intercourse, condom use at first, contraception, pregnancy, interruption of pregnancy)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Children Infected by HIV</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1 to 3 mL whole blood - 1 to 3mL plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort of HIV-infected children born to mothers included in ANRS-CO1 EPF or children under
        the age of 13 newly entered in care management with no prior antiretroviral therapy, whose
        mother was or not included in ANRS-CO1 EPF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected children born to mothers included in ANRS-CO1 EPF or children under the
             age of 13 newly entered in care management with no prior antiretroviral therapy, whose
             mother was or not included in ANRS-CO1 EPF

        Exclusion Criteria:

          -  &gt;= 13 years

          -  refusal of legal representative of the child

          -  antiretroviral therapy started before the entry in care management

          -  care management for over 6 months before inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josiane WARSZAWSKI</last_name>
    <role>Principal Investigator</role>
    <affiliation>CESP INSERM U1018</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josiane WARSZAWSKI</last_name>
    <phone>01 49 59 53 05</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivia DIALLA</last_name>
    <phone>01 49 59 53 13</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale FIALAIRE</last_name>
    </contact>
    <investigator>
      <last_name>Pascale FIALAIRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine CHIROUZE</last_name>
    </contact>
    <investigator>
      <last_name>Catherine CHIROUZE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LACHASSINE</last_name>
    </contact>
    <investigator>
      <last_name>Eric LACHASSINE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille RUNEL-BELLIARD</last_name>
    </contact>
    <investigator>
      <last_name>Camille RUNEL-BELLIARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques BROUARD</last_name>
    </contact>
    <investigator>
      <last_name>Jacques BROUARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe LABRUNE</last_name>
    </contact>
    <investigator>
      <last_name>Philippe LABRUNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne FLOCH-TUDAL</last_name>
    </contact>
    <investigator>
      <last_name>Corinne FLOCH-TUDAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Francilien Sud</name>
      <address>
        <city>Corbeil Essonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michèle GRANIER</last_name>
    </contact>
    <investigator>
      <last_name>Michèle GRANIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicëtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne FOURCADE</last_name>
    </contact>
    <investigator>
      <last_name>Corinne FOURCADE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Jeanne de Flandres</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise MAZINGUE</last_name>
    </contact>
    <investigator>
      <last_name>Françoise MAZINGUE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut d'Hématologie et Oncologie Pédiatrique</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamila KEBAILI</last_name>
    </contact>
    <investigator>
      <last_name>Kamila KEBAILI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel LALANDE</last_name>
    </contact>
    <investigator>
      <last_name>Muriel LALANDE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Montreuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte HELLER- ROUSSIN</last_name>
    </contact>
    <investigator>
      <last_name>Brigitte HELLER- ROUSSIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique RELIQUET</last_name>
    </contact>
    <investigator>
      <last_name>Véronique RELIQUET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital de l'Archet II</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice MONPOUX</last_name>
    </contact>
    <investigator>
      <last_name>Fabrice MONPOUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Cochin Tarnier Port-Royal</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghislaine FIRTION</last_name>
    </contact>
    <investigator>
      <last_name>Ghislaine FIRTION</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane BLANCHE</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane BLANCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine LEVINE</last_name>
    </contact>
    <investigator>
      <last_name>Martine LEVINE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine DOLLFUS</last_name>
    </contact>
    <investigator>
      <last_name>Catherine DOLLFUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général- Hôpital Delafontaine</name>
      <address>
        <city>Saint-denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal BOLOT</last_name>
    </contact>
    <investigator>
      <last_name>Pascal BOLOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Luisa PARTISANI</last_name>
    </contact>
    <investigator>
      <last_name>Maria Luisa PARTISANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Paule de Viguier</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joëlle TRICOIRE</last_name>
    </contact>
    <investigator>
      <last_name>Joëlle TRICOIRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général</name>
      <address>
        <city>Villeneuve Saint Georges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne CHACE</last_name>
    </contact>
    <investigator>
      <last_name>Anne CHACE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Frange P, Faye A, Avettand-Fenoël V, Bellaton E, Descamps D, Angin M, David A, Caillat-Zucman S, Peytavin G, Dollfus C, Le Chenadec J, Warszawski J, Rouzioux C, Sáez-Cirión A; ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV. 2016 Jan;3(1):e49-54. doi: 10.1016/S2352-3018(15)00232-5. Epub 2015 Dec 9.</citation>
    <PMID>26762993</PMID>
  </results_reference>
  <results_reference>
    <citation>Aupiais C, Faye A, Le Chenadec J, Rouzioux C, Bouallag N, Laurent C, Blanche S, Dollfus C, Warszawski J; ANRS EPF-CO10 French Pediatric Cohort. Interruption of cART in clinical practice is associated with an increase in the long-term risk of subsequent immunosuppression in HIV-1-infected children. Pediatr Infect Dis J. 2014 Dec;33(12):1237-45. doi: 10.1097/INF.0000000000000450.</citation>
    <PMID>24945880</PMID>
  </results_reference>
  <results_reference>
    <citation>Sofeu CL, Warszawski J, Ateba Ndongo F, Penda IC, Tetang Ndiang S, Guemkam G, Makwet N, Owona F, Kfutwah A, Tchendjou P, Texier G, Tchuente M, Faye A, Tejiokem MC; ANRS-PEDIACAM Study Group. Low birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon. PLoS One. 2014 Apr 3;9(4):e93554. doi: 10.1371/journal.pone.0093554. eCollection 2014.</citation>
    <PMID>24705410</PMID>
  </results_reference>
  <results_reference>
    <citation>Blanche S, Scott-Algara D, Le Chenadec J, Didier C, Montange T, Avettand-Fenoel V, Rouzioux C, Mélard A, Viard JP, Dollfus C, Bouallag N, Warszawski J, Buseyne F. Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in french adolescents and young adults infected in the perinatal period: the ANRS-EP38-IMMIP study. Clin Infect Dis. 2014 Feb;58(4):573-87. doi: 10.1093/cid/cit729. Epub 2013 Nov 18.</citation>
    <PMID>24253249</PMID>
  </results_reference>
  <results_reference>
    <citation>Avettand-Fenoel V, Blanche S, Le Chenadec J, Scott-Algara D, Dollfus C, Viard JP, Bouallag N, Benmebarek Y, Rivière Y, Warszawski J, Rouzioux C, Buseyne F. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. J Infect Dis. 2012 May 15;205(10):1520-8. doi: 10.1093/infdis/jis233. Epub 2012 Mar 15.</citation>
    <PMID>22427678</PMID>
  </results_reference>
  <results_reference>
    <citation>Goetghebuer T, Le Chenadec J, Haelterman E, Galli L, Dollfus C, Thorne C, Judd A, Keiser O, Ramos JT, Levy J, Warszawski J; European Infant Collaboration Group. Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis. 2012 Mar;54(6):878-81. doi: 10.1093/cid/cir950. Epub 2011 Dec 23.</citation>
    <PMID>22198788</PMID>
  </results_reference>
  <results_reference>
    <citation>Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens. AIDS. 2011 Nov 28;25(18):2279-87. doi: 10.1097/QAD.0b013e32834d614c.</citation>
    <PMID>21971357</PMID>
  </results_reference>
  <results_reference>
    <citation>Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chene G, Phillips A. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet. 2011 May 7;377(9777):1580-7. doi: 10.1016/S0140-6736(11)60208-0. Epub 2011 Apr 20.</citation>
    <PMID>21511330</PMID>
  </results_reference>
  <results_reference>
    <citation>Dollfus C, Le Chenadec J, Faye A, Blanche S, Briand N, Rouzioux C, Warszawski J. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10). Clin Infect Dis. 2010 Jul 15;51(2):214-24. doi: 10.1086/653674.</citation>
    <PMID>20536367</PMID>
  </results_reference>
  <results_reference>
    <citation>Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, Green H, Galli L, Ramos JT, Giaquinto C, Warszawski J, Levy J; European Infant Collaboration group. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS. 2009 Mar 13;23(5):597-604. doi: 10.1097/QAD.0b013e328326ca37.</citation>
    <PMID>19194272</PMID>
  </results_reference>
  <results_reference>
    <citation>Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J. Response to combination antiretroviral therapy: variation by age. AIDS. 2008 Jul 31;22(12):1463-73. doi: 10.1097/QAD.0b013e3282f88d02.</citation>
    <PMID>18614870</PMID>
  </results_reference>
  <results_reference>
    <citation>Warszawski J, Lechenadec J, Faye A, Dollfus C, Firtion G, Meyer L, Douard D, Monpoux F, Tricoire J, Benmebarek Y, Rouzioux C, Blanche S. Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort. Clin Infect Dis. 2007 Sep 15;45(6):785-94. Epub 2007 Aug 14.</citation>
    <PMID>17712765</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Infection</keyword>
  <keyword>Adolescent</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

